Natural History of Visual Dysfunction in ABCA4 Retinopathy and Its Genetic Correlates.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37211138.
- Also identified by DOI 10.1016/j.ajo.2023.05.014 and PMC identifier 10524499.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To systematically assess the ability to detect change and retest reliability for a panel of visual function assessments in ABCA4 retinopathy. Prospective natural history study (NCT01736293). Patients with at least 1 documented pathogenic ABCA4 variant and a clinical phenotype consistent with ABCA4 retinopathy were recruited from a tertiary referral center. Participants underwent longitudinal, multifaceted functional testing, including measures of function at fixation (best-corrected visual acuity, low-vision Cambridge Color Test), macular function (microperimetry), and retina-wide function (full-field electroretinography [ERG]). Two- and 5-year ability to detect change was determined based on the η<sup>2</sup> statistic. A total of 134 eyes from 67 participants with a mean follow-up of 3.65 years were included. In the 2-year interval, the microperimetry-derived perilesional sensitivity (η<sup>2</sup> of 0.73 [0.53, 0.83]; -1.79 dB/y [-2.2, -1.37]) and mean sensitivity (η<sup>2</sup> of 0.62 [0.38, 0.76]; -1.28 dB/y [-1.67, -0.89]) showed most change over time, but could only be recorded in 71.6% of the participants. In the 5-year interval, the dark-adapted ERG a- and b-wave amplitude showed marked change over time as well (eg, DA 30 a-wave amplitude with an η<sup>2</sup> of 0.54 [0.34, 0.68]; -0.02 log<sub>10</sub>(µV)/y [-0.02, -0.01]). The genotype explained a large fraction of variability in the ERG-based age of disease initiation (adjusted R<sup>2</sup> of 0.73) CONCLUSIONS: Microperimetry-based clinical outcome assessments were most sensitive to change but could only be acquired in a subset of participants. Across a 5-year interval, the ERG DA 30 a-wave amplitude was sensitive to disease progression, potentially allowing for more inclusive clinical trial designs encompassing the whole ABCA4 retinopathy spectrum.
Medical subject headings
- Visual Fields
- Retinal Diseases